EUVIMEDEUVIMED entdecken
Open Access

Comparison of Durability Between Rezum Water Vapor Therapy and UroLift in Treating Benign Prostatic Hyperplasia: A Multicenter Propensity Score-Matched Analysis

Chye-Yang Lim, Chih-Cheng Lai, Ya-Wen Tsai

Cureus · 20.03.2025

DOI: 10.7759/cureus.80914 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cureus, erschienen am 20.03.2025. Verfasst von Chye-Yang Lim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, TWN. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rezum water vapor therapy and UroLift are among the minimally invasive surgical therapies (MISTs) gaining popularity in the treatment of benign prostatic hyperplasia (BPH). This study aims to evaluate and compare the reintervention rates, a measure of durability, for Rezum water vapor therapy and UroLift as MISTs for BPH.

Methods

We conducted a retrospective cohort study using data from the TriNetX Global Collaborative Network, a large database of electronic health records from January 2014 to June 2024. Current Procedural Terminology (CPT) and International Classification of Diseases 10th Revision codes (ICD-10) were used to build the cohorts of men aged over 18 years who underwent either Rezum water vapor therapy or UroLift. Reintervention rates and complication profiles were evaluated over a follow-up period of up to five years.

Results

Cumulative reintervention rates were collected for both Rezum water vapor therapy and UroLift at the 1st, 3rd, and 5th years (2.83% vs. 3.59%, 5.99% vs. 8.76%, 6.81% vs. 10.85%). The average annual increase rate was 1% for Rezum water vapor therapy compared with 1.82% for UroLift, respectively. Most complications were more prominent in the Rezum water vapor therapy group, with urinary retention accounting for 23.42%.

Discussion

Rezum water vapor therapy demonstrates a more durable effect with lower reintervention rates compared to UroLift, based on this large multicenter cohort study. The higher reintervention rate observed with UroLift may reflect differences in the mechanisms of action between the two procedures.

Conclusions

These findings elucidate the superiority of Rezum water vapor therapy in sustaining the therapeutic effect over the long term compared to UroLift. However, more complications were noted in the Rezum water vapor therapy group. Thus, clinicians should take into account the durability and complication profiles in shared decision-making when considering MISTs for BPH.

Schlagwörter

Stichwörter der Autor:innen

benign prostatic hyperplasiacomplicationsdurabilityreinterventionrezum water vapor therapytrinetx databaseurolift

Autor:innen und Institutionen

  • Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, TWN.
  • Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, TWN.
  • School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, TWN.
  • Division of Preventive Medicine, Chi Mei Medical Center, Tainan, TWN.

Zitieren

APA

Lim, C. Y., Lai, C. C., & Tsai, Y. W. (2025). Comparison of Durability Between Rezum Water Vapor Therapy and UroLift in Treating Benign Prostatic Hyperplasia: A Multicenter Propensity Score-Matched Analysis. Cureus. https://doi.org/10.7759/cureus.80914

Vancouver

Lim CY, Lai CC, Tsai YW. Comparison of Durability Between Rezum Water Vapor Therapy and UroLift in Treating Benign Prostatic Hyperplasia: A Multicenter Propensity Score-Matched Analysis. Cureus. 2025. doi:10.7759/cureus.80914

BibTeX
@article{Lim2025,
  author = {Lim, Chye-Yang and Lai, Chih-Cheng and Tsai, Ya-Wen},
  title = {Comparison of Durability Between Rezum Water Vapor Therapy and UroLift in Treating Benign Prostatic Hyperplasia: A Multicenter Propensity Score-Matched Analysis},
  journal = {Cureus},
  year = {2025},
  doi = {10.7759/cureus.80914}
}
Kostenlos starten →